Literature DB >> 31468499

When Low Bone Mineral Density and Fractures Is Not Osteoporosis.

Smita Jha1,2, Marquis Chapman3, Kelly Roszko4.   

Abstract

PURPOSE OF REVIEW: To review the differential diagnosis of low bone mineral density (BMD). RECENT
FINDINGS: Osteoporosis is the most common cause of low BMD in adults; however, non-osteoporotic causes of low BMD should be considered in the differential diagnosis of patients with low BMD. Mild osteogenesis imperfecta, osteomalacia, and mineral and bone disorder of chronic kidney disease as well as several other rare diseases can be characterized by low BMD. This review summarizes the differential diagnosis of low BMD. It is important to differentiate osteoporosis from other causes of low BMD since treatment regimens can vary tremendously between these different disease processes. In fact, some treatments for osteoporosis could worsen or exacerbate the mineral abnormalities in other causes of low BMD.

Entities:  

Keywords:  CKD-MBD, DXA; Neurofibromatosis; Osteogenesis imperfecta; Osteomalacia; Rare diseases

Mesh:

Year:  2019        PMID: 31468499      PMCID: PMC6819255          DOI: 10.1007/s11914-019-00529-7

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  82 in total

1.  Evaluation of bone mineral density and microarchitectural parameters by DXA and HR-pQCT in 37 children and adults with X-linked hypophosphatemic rickets.

Authors:  G P Colares Neto; R M R Pereira; J C Alvarenga; L Takayama; M F A Funari; R M Martin
Journal:  Osteoporos Int       Date:  2017-02-13       Impact factor: 4.507

2.  Targeted Disruption of NF1 in Osteocytes Increases FGF23 and Osteoid With Osteomalacia-like Bone Phenotype.

Authors:  Nobuhiro Kamiya; Ryosuke Yamaguchi; Olumide Aruwajoye; Audrey J Kim; Gen Kuroyanagi; Matthew Phipps; Naga Suresh Adapala; Jian Q Feng; Harry Kw Kim
Journal:  J Bone Miner Res       Date:  2017-05-23       Impact factor: 6.741

3.  Factors associated with low bone mineral density in patients with cystic fibrosis.

Authors:  Shahid Sheikh; Susan Gemma; Alpa Patel
Journal:  J Bone Miner Metab       Date:  2014-03-16       Impact factor: 2.626

4.  Mechanism of FGF23 processing in fibrous dysplasia.

Authors:  Nisan Bhattacharyya; Malgorzata Wiench; Claudia Dumitrescu; Brian M Connolly; Thomas H Bugge; Himatkumar V Patel; Rachel I Gafni; Natasha Cherman; Monique Cho; Gordon L Hager; Michael T Collins
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

5.  Enzyme-replacement therapy in life-threatening hypophosphatasia.

Authors:  Michael P Whyte; Cheryl R Greenberg; Nada J Salman; Michael B Bober; William H McAlister; Deborah Wenkert; Bradley J Van Sickle; Jill H Simmons; Terence S Edgar; Martin L Bauer; Mohamed A Hamdan; Nick Bishop; Richard E Lutz; Mairead McGinn; Stanley Craig; Jean N Moore; John W Taylor; Robert H Cleveland; William R Cranley; Ruth Lim; Tom D Thacher; Jill E Mayhew; Matthew Downs; José Luis Millán; Alison M Skrinar; Philippe Crine; Hal Landy
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

6.  Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.

Authors:  Young H Lim; Diana Ovejero; Jeffrey S Sugarman; Cynthia M C Deklotz; Ann Maruri; Lawrence F Eichenfield; Patrick K Kelley; Harald Jüppner; Michael Gottschalk; Cynthia J Tifft; Rachel I Gafni; Alison M Boyce; Edward W Cowen; Nisan Bhattacharyya; Lori C Guthrie; William A Gahl; Gretchen Golas; Erin C Loring; John D Overton; Shrikant M Mane; Richard P Lifton; Moise L Levy; Michael T Collins; Keith A Choate
Journal:  Hum Mol Genet       Date:  2013-09-04       Impact factor: 6.150

Review 7.  Fanconi Syndrome.

Authors:  John W Foreman
Journal:  Pediatr Clin North Am       Date:  2019-02       Impact factor: 3.278

Review 8.  Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.

Authors:  Young H Lim; Diana Ovejero; Kristina M Derrick; Michael T Collins; Keith A Choate
Journal:  J Am Acad Dermatol       Date:  2016-08       Impact factor: 11.527

Review 9.  The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis.

Authors:  J Paccou; N Zeboulon; C Combescure; L Gossec; B Cortet
Journal:  Calcif Tissue Int       Date:  2009-12-01       Impact factor: 4.333

10.  Different missense mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia.

Authors:  P S Henthorn; M Raducha; K N Fedde; M A Lafferty; M P Whyte
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

View more
  5 in total

Review 1.  Evaluating Patients for Secondary Causes of Osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Curr Osteoporos Rep       Date:  2022-01-15       Impact factor: 5.096

2.  Response of the ENPP1-Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice.

Authors:  Carlos R Ferreira; Dillon Kavanagh; Ralf Oheim; Kristin Zimmerman; Julian Stürznickel; Xiaofeng Li; Paul Stabach; R Luke Rettig; Logan Calderone; Colin MacKichan; Aaron Wang; Hunter A Hutchinson; Tracy Nelson; Steven M Tommasini; Simon von Kroge; Imke Ak Fiedler; Ethan R Lester; Gilbert W Moeckel; Björn Busse; Thorsten Schinke; Thomas O Carpenter; Michael A Levine; Mark C Horowitz; Demetrios T Braddock
Journal:  J Bone Miner Res       Date:  2021-02-18       Impact factor: 6.741

3.  Weight change and fracture risk in patients with diabetic kidney disease: A nationwide population-based study.

Authors:  Chang Seong Kim; Hong Sang Choi; Eun Hui Bae; Seong Kwon Ma; Bongseong Kim; Kyung-Do Han; Soo Wan Kim
Journal:  Front Med (Lausanne)       Date:  2022-07-28

Review 4.  Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis.

Authors:  Jingfei Fu; Yanxue Wang; Yiyang Jiang; Juan Du; Junji Xu; Yi Liu
Journal:  Stem Cell Res Ther       Date:  2021-07-02       Impact factor: 6.832

Review 5.  Factors influencing peak bone mass gain.

Authors:  Xiaowei Zhu; Houfeng Zheng
Journal:  Front Med       Date:  2020-06-09       Impact factor: 4.592

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.